Please use this identifier to cite or link to this item:
|Title:||Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease.|
|Authors:||Siddiqui, Salman H.|
Wedzicha, J. A.
|Publisher:||American Thoracic Society|
|Citation:||American Journal of Respiratory and Critical Care Medicine, 2015|
|Abstract:||Rationale. Blood eosinophilia has been shown to be associated with a significant proportion of COPD exacerbations and stratifies the clinical response to systemic corticosteroids. The FORWARD study was a randomised, double-blind, parallel group trial that compared 48 weeks treatment with extrafine beclomethasone dipropionate plus formoterol fumarate (BDP/FF) vs. FF, in severe COPD patients with a history of exacerbations. Objectives. We hypothesised that there would be treatment differences in response to BDP/FF when stratifying by baseline blood eosinophil count in a post hoc analysis. Methods. The patients (N=1,184) were stratified into four quartile groups based on the baseline eosinophil count and analyses on exacerbation rate, change in pre dose FEV1 and St. George’s Respiratory Questionnaire [SGRQ] total score over 48 weeks were performed across these. A predictive model of future exacerbations was developed based upon baseline blood eosinophil count and other factors. Results. The adjusted treatment difference over 48 weeks between the BDP/FF and FF groups was largest within the highest baseline blood eosinophil quartile (≥279.8/µl /µl). Within this quartile a significant (i) 46% reduction in exacerbation rate, (ii) 0.102 L improvement in pre bronchodilator FEV1 and (iii) 5.9 units improvement in SGRQ total score were seen in favour of BDP/FF. Predictive modelling suggested that the risk of exacerbations was influenced by baseline blood eosinophils in patients treated with FF alone, but not in patients treated with BDP/FF. Conclusions. The presence of a significant blood eosinophilia seems to be associated with a particularly favorable response to ICS/LABA therapy in COPD patients.|
|Rights:||Archived with reference to SHERPA/RoMEO and publisher website. Originally Published in: Salman H Siddiqui , Alessandro Guasconi , Jørgen Vestbo , Paul Jones , Alvar Agustí , Pierluigi Paggiaro , Jadwiga A. Wedzicha , and Dave Singh. Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine 2015 DOI: 10.1164/rccm.201502-0235LE Copyright © 2015 by the American Thoracic Society The final publication is available at http://www.atsjournals.org/doi/10.1164/rccm.201502-0235LE|
|Appears in Collections:||Published Articles, Dept. of Infection, Immunity and Inflammation|
Files in This Item:
|FORWARD_EOSINOPHILS_R2.pdf||Post-review (final submitted)||1.23 MB||Adobe PDF||View/Open|
Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.